Investors Press Releases Year All2024202320222021 Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research Aug 14, 2024 Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Aug 06, 2024 Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors Jun 24, 2024 Omega Therapeutics To Participate In Two Upcoming Investor Conferences May 30, 2024 Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer May 29, 2024 Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers May 08, 2024 Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress May 06, 2024 Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting Apr 23, 2024 Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control Apr 09, 2024 Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update Mar 28, 2024
Year All2024202320222021 Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research Aug 14, 2024 Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Aug 06, 2024 Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors Jun 24, 2024 Omega Therapeutics To Participate In Two Upcoming Investor Conferences May 30, 2024 Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer May 29, 2024 Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers May 08, 2024 Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress May 06, 2024 Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting Apr 23, 2024 Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control Apr 09, 2024 Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update Mar 28, 2024
